Company profile
DIAGNOS Inc.
OTC: DGNOF · Healthcare · Medical - Healthcare Information Services
Canadian filerHQ Brossard, QCReports USD
#1084 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
29DFH 23DQ —GM 32SS 58
v0.1 · 45/100 weight · provisional
↑ listing tenure, growth stability · ↓ return on equity, operating margin
Methodology →Revenue TTM
$47.4k
Rev growth YoY (TTM)
-36.7%
Net income (FY)
-$3.3M
Employees
22
as of 2026-08-21
Market cap
$33.7M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$47.5k65.6k CAD2026
Net income-$3.3M-4.6M CAD2026
Operating income-$3.1M-4.3M CAD2026
Total assets$1.7M2.4M CAD2026
Liabilities$1.2M1.7M CAD2026
Equity$494.1k688.7k CAD2026
Revenue trend
FY2019 – FY2026 · USD
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY26
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is DIAGNOS Inc.’s revenue?
DIAGNOS Inc. booked $47.5k in FY2026 revenue, contracting 36% year over year — slower than 78% of Healthcare companies we track, at a -6957.0% net margin.
Peers · Healthcare
INmune Bio, Inc.41DMultiCell Technologies, Inc.——Ovation Science Inc.23DCalidi Biotherapeutics, Inc.19DMillennium Sustainable Ventures Corp.——Altimmune, Inc.55CKey facts
CEOAndre Larente
SectorHealthcare
IndustryMedical - Healthcare Information Services
HeadquartersBrossard, QC
ExchangeOTC: DGNOF
Employees22
IPO date2003-06-24
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.